Exelixis has announced the availability of Cometriq (cabozantinib), indicated for medullary thyroid cancer (MTC), in the US.
Diplomat Specialty Pharmacy is distributing the product across the US.
Cometriq that is developed to inhibit the activity of tyrosine kinases including RET, MET and VEGFR2, obtained FDA clearance for marketing in November 2012.
The receptor tyrosine kinases play a vital role in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/exelixis-makes-cometriq-available-in-us-250113
